keyword
MENU ▼
Read by QxMD icon Read
search

Non-alcoholic steatohepatitis

keyword
https://www.readbyqxmd.com/read/28726335/preperitoneal-fat-as-a-noninvsasive-marker-of-increased-risk-of-severe-non-alcoholic-fatty-liver-disease-in-patients-with-type-2-diabetes
#1
Daniella Braz Parente, Jaime Araújo Oliveira Netso, Pedro Emmanuel Alvarenga Americano Brasil, Fernando Fernandes Paiva, José Pedro Rodrigues Ravani, Marilia Brito Gomes, Valeria Lanzoni, Carlos Frederico Ferreira Campos, Lilian Machado-Silva, Renata Mello Perez, Rosana Souza Rodrigues
BACKGROUND AND AIM: Fat distribution may have prognostic value in the evaluation of non-alcoholic fatty liver disease. This study was conducted to evaluate associations of MRI-measured abdominal fat areas with steatosis, steatohepatitis, and fibrosis, assessed histopathologically, in patients with type 2 diabetes. METHODS: This prospective study included 66 patients with type 2 diabetes (12 males, 54 females, age 26-68 years), without chronic liver disease of other causes...
July 20, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28725667/data-on-lipocalin-2-and-phosphatidylinositol-3-kinase-signaling-in-a-methionine-and-choline-deficient-model-of-non-alcoholic-steatohepatitis
#2
Anastasia Asimakopoulou, Erawan Borkham-Kamphorst, Eddy Van de Leur, Ralf Weiskirchen
The data presented in this brief report support the research article "Altered mitochondrial and peroxisomal integrity in lipocalin-2-deficient mice with hepatic steatosis" [1, doi: 10.1016/j.bbadis.2017.04.006]. We tested whether the absence of Lipocalin-2 (LCN2) could dysregulate the phosphatidylinositol 3-kinase/protein kinase B (PI3K-PKB) pathway and hepatic homeostasis in Non-Alcoholic-Steatohepatitis (NASH). The article highlights the role of LCN2 in hepatic homeostasis.
August 2017: Data in Brief
https://www.readbyqxmd.com/read/28724274/the-correlation-between-liver-fat-content-and-ulcerative-colitis-disease-severity
#3
Raika Jamali, Mohammad Biglari, Seyyed Vahid Seyyed Hosseini, Ali Shakouri Rad, Farid Kosari
To evaluate the association between disease severity and hepatic steatosis in patients with ulcerative colitis (UC) and non-alcoholic steatohepatitis (NASH). Consecutively selected UC patients admitted to the gastroenterology clinic were enrolled in the study. UC severity was assessed by Truelove and Witts classification. Patients with severe UC were excluded from the study. NASH was determined based on persistently elevated serum aminotransferase levels and detection of fatty liver ultrasound. Patients with other etiologies for elevated aminotransferase levels were excluded...
May 2017: Acta Medica Iranica
https://www.readbyqxmd.com/read/28723981/intestinal-microbiota-in-digestive-diseases
#4
Maria do Carmo Friche Passos, Joaquim Prado Moraes-Filho
BACKGROUND: In recent years, especially after the development of sophisticated metagenomic studies, research on the intestinal microbiota has increased, radically transforming our knowledge about the microbiome and its association with health maintenance and disease development in humans. Increasing evidence has shown that a permanent alteration in microbiota composition or function (dysbiosis) can alter immune responses, metabolism, intestinal permeability, and digestive motility, thereby promoting a proinflammatory state...
July 6, 2017: Arquivos de Gastroenterologia
https://www.readbyqxmd.com/read/28720429/stable-isotope-based-flux-studies-in-nonalcoholic-fatty-liver-disease
#5
REVIEW
Arthur McCullough, Stephen Previs, Takhar Kasumov
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and is associated with the worldwide epidemics of obesity, diabetes and cardiovascular diseases. NAFLD ranges from benign fat accumulation in the liver (steatosis) to non-alcoholic steatohepatitis (NASH), and cirrhosis which can progress to hepatocellular carcinoma and liver failure. Mass spectrometry and magnetic resonance spectroscopy-coupled stable isotope-based flux studies provide new insights into the understanding of NAFLD pathogenesis and the disease progression...
July 15, 2017: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28719078/luseogliflozin-improves-liver-fat-deposition-compared-to-metformin-in-type-2-diabetes-patients-with-non-alcoholic-fatty-liver-disease-a-prospective-randomized-controlled-pilot-study
#6
Takashi Shibuya, Nobutoshi Fushimi, Miyuka Kawai, Yohei Yoshida, Hiroki Hachiya, Shun Ito, Hiromi Kawai, Noritsugu Ohashi, Akihiro Mori
Non-alcoholic fatty liver disease (NAFLD) often coexists with type 2 diabetes (T2D), and its prevalence in patients with T2D is estimated to be approximately 50%-60% in Japan.(1) In some patients with T2D, NAFLD can progress to non-alcoholic steatohepatitis (NASH) and further to liver cirrhosis and hepatocellular carcinoma (HCC).(2) Moreover, NAFLD is considered an independent risk factor for cardiovascular events.(3).
July 18, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28718215/usp18-protects-against-hepatic-steatosis-and-insulin-resistance-via-its-dub-activity
#7
Shimin An, Ling-Ping Zhao, Li-Jun Shen, Siyuan Wang, Kuo Zhang, Yu Qi, Jilin Zheng, Xiao-Jing Zhang, Xue-Yong Zhu, Rong Bao, Ling Yang, Yue-Xin Lu, Zhi-Gang She, Yi-Da Tang
Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis, impaired insulin sensitivity and chronic low-grade inflammation. However, the pathogenic mechanism of NAFLD is poorly understood, which hinders the exploration of possible treatments. Here, we first report that ubiquitin-specific protease 18 (USP18), a member of the deubiquitinating (DUB) enzyme family, plays regulatory roles in NAFLD progression. The expression of USP18 was down-regulated in the livers of non-alcoholic steatohepatitis (NASH) patients and high-fat diet (HFD) induced or genetically obese mice...
July 17, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28715695/new-liver-cancer-biomarkers-pi3k-akt-mtor-pathway-members-and-eukaryotic-translation-initiation-factors
#8
Nicole Golob-Schwarzl, Stefanie Krassnig, Anna M Toeglhofer, Young Nyun Park, Margit Gogg-Kamerer, Klemens Vierlinger, Fabian Schröder, Hyungjn Rhee, Rudolf Schicho, Peter Fickert, Johannes Haybaeck
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. The initiation of protein translation is an important rate-limiting step in eukaryotes and is crucial in many viral infections. Eukaryotic translation initiation factors (eIFs) are involved in the initiation step of protein translation and are linked to the phosphatidylinositol-3-kinases PI3K/AKT/mTOR pathway. Therefore we aimed to investigate a potential role of eIFs in HCC. We herein report on the immunohistochemical expression of the various eIF subunits in 235 cases of virus-related human HCC...
July 14, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28714405/emerging-targets-to-relieve-fat-stress-induced-liver-diseases-udca-tocotrienol-%C3%AF-3-pufas-and-igy-targeted-npc1l1-cholesterol-transporter
#9
Ji-Young Cha, Jong-Min Park, Ho-Jae Lee, Jin-Sik Bae, Young-Min Han, Byung-Chul Oh, Kwang Hyun Ko, Ki-Baik Hahm
Fat stress-induced liver disease is a hepatic manifestation of metabolic syndrome initiated by excess fat accumulation and encompasses a wide spectrum of diseases from non-alcoholic fatty liver disease to non-alcoholic steatohepatitis, a precursor lesion progressing to more aggressive liver cirrhosis and hepatocellular carcinoma. Although the incidence of these fat stress-induced liver diseases is rapidly increasing worldwide in parallel with the growing epidemics of obesity and metabolic diseases, its exact pathogenesis is not well defined...
July 14, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28711599/arachidonic-acid-sex-dependently-affects-obesity-through-linking-gut-microbiota-driven-inflammation-to-hypothalamus-adipose-liver-axis
#10
Pan Zhuang, Qiyang Shou, Yanhua Lu, Guangfa Wang, Jieni Qiu, Jun Wang, Lilin He, Jingnan Chen, Jingjing Jiao, Yu Zhang
Unraveling the role of dietary lipids is beneficial to treat obesity and metabolic dysfunction. Nonetheless, how dietary lipids affect existing obesity remains unknown. Arachidonic acid (AA), a derivative of linoleic acid, is one of the crucial n-6 fatty acids. The aim of this study was to investigate whether AA affects obesity through associating microbiota-driven inflammation with hypothalamus-adipose-liver axis. Four-week old C57BL/6J mice were fed with a high-fat diet (HFD, 45% fat) for 10 weeks to induce obesity, and then fed a HFD enriched with 10 g/kg of AA or a continuous HFD in the following 15 weeks...
July 12, 2017: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/28710282/function-of-inhibitor-of-brutons-tyrosine-kinase-isoform-%C3%AE-ibtk%C3%AE-in-nonalcoholic-steatohepatitis-links-autophagy-and-the-unfolded-protein-response
#11
Jeffrey A Willy, Sara K Young, Amber L Mosley, Samer Gawrieh, James L Stevens, Howard C Masuoka, Ronald C Wek
Nonalcoholic fatty liver disease (steatosis) is the most prevalent liver disease in the Western world. One of the advanced pathologies is non Non-alcoholic steatohepatitis (NASH), which is associated with induction of the Unfolded protein response (UPR) and disruption of autophagic flux. However, the mechanisms by which these processes contribute to the pathogenesis of human diseases are unclear. Herein we identify the α isoform of the inhibitor of Brutons tyrosine kinase (IBTKα) as a member of the UPR whose expression is preferentially translated during endoplasmic reticulum (ER) stress...
July 14, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/28702667/microengineered-cultures-containing-human-hepatic-stellate-cells-and-hepatocytes-for-drug-development
#12
Matthew D Davidson, David A Kukla, Salman R Khetani
In non-alcoholic steatohepatitis (NASH), hepatic stellate cells (HSC) differentiate into myofibroblast-like cells that cause fibrosis, which predisposes patients to cirrhosis and hepatocellular carcinoma. Thus, modeling interactions between activated HSCs and hepatocytes in vitro can aid in the development of anti-NASH/fibrosis therapeutics and lead to a better understanding of disease progression. Species-specific differences in drug metabolism and disease pathways now necessitate the supplementation of animal studies with data acquired using human liver models; however, current models do not adequately model the negative effects of primary human activated HSCs on the phenotype of otherwise well-differentiated primary human hepatocytes (PHHs) as in vivo...
July 12, 2017: Integrative Biology: Quantitative Biosciences From Nano to Macro
https://www.readbyqxmd.com/read/28699612/relationship-between-immune-parameters-and-non-alcoholic-fatty-liver-disease-in-obese-children
#13
Jun-Qi Shi, Wen-Xia Shen, Xiang-Zhi Wang, Ke Huang, Chao-Chun Zou
OBJECTIVE: To investigate the relationship between immune parameters and non-alcoholic fatty liver disease (NAFLD) in obese children. DESIGN: Case-control study. SETTING: Zhejiang Province, China on July to September 2015. PARTICIPANTS: A total of 117 obese children and 209 healthy non-obese children were studied as the obese and control groups. Depending on the severity of NAFLD, the obese group was divided into subgroups 1 (without NAFLD), 2 (with simple fatty liver) and 3 (with steatohepatitis)...
July 11, 2017: Indian Pediatrics
https://www.readbyqxmd.com/read/28698650/complementary-role-of-fibroblast-growth-factor-21-and-cytokeratin-18-in-monitoring-the-different-stages-of-nonalcoholic-fatty-liver-disease
#14
Guangyu Wu, Huating Li, Qichen Fang, Jing Zhang, Mingliang Zhang, Lei Zhang, Liang Wu, Xuhong Hou, Junxi Lu, Yuqian Bao, Weiping Jia
Fibroblast growth factor 21 (FGF21) and cytokeratin 18 (CK18) were previously reported to be elevated in nonalcoholic fatty liver disease (NAFLD). We aim to analyze the differential roles of FGF21, cell apoptosis marker CK18 fragment M30 and total cell death marker CK18 M65ED in monitoring the different stages of NAFLD spectrum in a population-based prospective cohort comprising 808 Chinese subjects. Predictive performances for monitoring the different stages of NAFLD were assessed by logistic regression and receiver-operating characteristic (ROC) curves...
July 11, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28696785/exendin-4-a-glucagon-like-peptide-1-receptor-agonist-downregulates-hepatic-receptor-for-advanced-glycation-end-products-in-non-alcoholic-steatohepatitis-rat-model
#15
Mona M Allam, Walaa B El Gazzar
CONTEXT: Exendin-4, a glucagon-like peptide-1 receptor agonist has been shown to have curative effects on hepatic steatosis in murine models. OBJECTIVE: The present study aimed to elucidate the effect of Exendin-4 on hepatic receptor for advanced glycation end products (RAGE) mRNA expression in non-alcoholic steatohepatitis (NASH) rat model induced by high-fat diet. METHODS: NASH was induced by high-fat diet intake, and Exendin-4 was given in two different doses...
July 11, 2017: Archives of Physiology and Biochemistry
https://www.readbyqxmd.com/read/28695813/value-of-acoustic-radiation-force-impulse-imaging-in-the-diagnosis-of-early-non-alcoholic-steatohepatitis
#16
(no author information available yet)
Objective To evaluate the value of acoustic radiation force impulse(ARFI)imaging in the diagnosis of early non-alcoholic steatohepatitis(NASH).Methods Totally 32 SD rats were randomly divided into high-fat diet group(n=24)and normal-diet group(n=8)by using the random number table. At the end of the 4(th),8(th),12(th),and 16(th) week,six rats from the high-diet group and two rats from the normal-diet group were selected blindly for weighting,blood biochemical test,conventional ultrasound,and ARFI imaing. HE staining was used for pathological observation...
June 20, 2017: Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae
https://www.readbyqxmd.com/read/28693358/anti-steatosis-compounds-from-leaves-of-mallotus-furetianus
#17
Xuedan Huang, Mingzhu Xu, Tatsuya Shirahata, Wei Li, Kazuo Koike, Akiko Kojima-Yuasa, Isao Yuasa, Yoshinori Kobayashi
There is no drug administration-approved therapy for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). In this study, eight compounds, gallic acid (1), methyl gallate (2), corilagin (3), 3,4,8,9,10-pentahydroxydibenzo[b,d]pyran-6-one (4), repandinin B (5), (Z)-3-hexenyl-β-D-glucopyranoside (6), (+)-lyoniresinol-3α-O-α-L-rhamnopyranoside (7) and mallophenol A (8) were isolated from the active fractions of Mallotus furetianus. Three compounds, (6, 7 and 8) revealed potent anti-steatosis activity in the oleic acid (OA)-induced steatosis cell model, with the minimum effective concentration of 0...
July 10, 2017: Natural Product Research
https://www.readbyqxmd.com/read/28689548/-non-alcoholic-fatty-liver-disease-in-children-and-adolescents
#18
Jessica Björklund, Tea Lund Laursen, Konstantin Kazankov, Karen Louise Thomsen, Stephen Hamilton-Dutoit, Elisabeth Stenbøg, Henning Grønbæk
Non-alcoholic fatty liver disease (NAFLD) is characterized by liver fat accumulation and non-alcoholic steatohepatitis (NASH) with inflammation and fibrosis, which may lead to cirrhosis also in childhood. NAFLD/NASH in children are related to obesity and the metabolic syndrome, and incidence and prevalence are expected to increase. Children having liver steatosis and elevated liver enzymes are most often asymptomatic, and a liver biopsy is necessary for correct diagnosis and staging. The treatment should focus on lifestyle changes, as pharmacological therapy needs further evaluation...
July 3, 2017: Ugeskrift for Laeger
https://www.readbyqxmd.com/read/28687459/mouse-models-of-nonalcoholic-steatohepatitis-in-preclinical-drug-development
#19
REVIEW
Henrik H Hansen, Michael Feigh, Sanne S Veidal, Kristoffer T Rigbolt, Niels Vrang, Keld Fosgerau
Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease in the Western world. NAFLD is a complex spectrum of liver diseases ranging from benign hepatic steatosis to its more aggressive necroinflammatory manifestation, nonalcoholic steatohepatitis (NASH). NASH pathogenesis is multifactorial and risk factors are almost identical to those of the metabolic syndrome. This has prompted substantial efforts to identify novel drug therapies for correcting underlying metabolic deficits, and to prevent or alleviate hepatic fibrosis in NASH...
July 4, 2017: Drug Discovery Today
https://www.readbyqxmd.com/read/28685692/molecular-determinants-of-chronic-liver-disease-as-studied-by-nmr-metabolomics
#20
Nieves Embade, Oscar Millet
Chronic liver diseases are one of the major causes of mortality worldwide. It can manifest through many different forms including chronic virus infection, alcohol abuse, metabolic syndromes such as non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. At early stages, the liver can repair the damage produced by the insult. However, upon continuous damage, the accumulation of molecules triggers fibrosis, which subsequently progresses towards cirrhosis and, ultimately, hepatocarcinoma. Early diagnosis of liver disease and a proper staging of fibrosis are crucial in therapy since drugs are only effective at incipient and intermediate stages of the disease...
July 7, 2017: Current Topics in Medicinal Chemistry
keyword
keyword
12440
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"